BioAtla, Inc. (NASDAQ:BCAB) Short Interest Up 11.4% in January

BioAtla, Inc. (NASDAQ:BCAB) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 4,400,000 shares, a growth of 11.4% from the December 31st total of 3,950,000 shares. Based on an average trading volume of 1,120,000 shares, the short-interest ratio is presently 3.9 days.

Analyst Ratings Changes

Separately, HC Wainwright cut shares of BioAtla from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 13th.

BioAtla Trading Down 3.4 %

Shares of BCAB traded down $0.02 during trading hours on Monday, hitting $0.45. 1,186,415 shares of the stock traded hands, compared to its average volume of 1,048,391. The business has a fifty day moving average of $0.92 and a 200-day moving average of $1.50. The firm has a market capitalization of $21.96 million, a PE ratio of -0.27 and a beta of 1.14. BioAtla has a 1-year low of $0.43 and a 1-year high of $4.02.

BioAtla (NASDAQ:BCAB) last issued its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.12. The business had revenue of $11.00 million during the quarter. During the same quarter in the previous year, the business earned ($0.70) earnings per share. As a group, equities research analysts expect that BioAtla will post -1.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioAtla

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Magnus Financial Group LLC acquired a new position in BioAtla during the fourth quarter valued at approximately $28,000. XTX Topco Ltd increased its position in shares of BioAtla by 7.2% in the 3rd quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock valued at $273,000 after buying an additional 10,384 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of BioAtla by 5.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company’s stock valued at $1,002,000 after buying an additional 28,133 shares in the last quarter. GSA Capital Partners LLP acquired a new position in BioAtla in the third quarter valued at about $623,000. Finally, Chicago Partners Investment Group LLC acquired a new stake in shares of BioAtla during the third quarter worth about $44,000. Institutional investors own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.